Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
58166-83-9
Molecular formula
C18H23N5O3
Molecular weight
357.4 g/mol
Drug class
Sympathomimetic vasopressor component of fixed cafedrine/theodrenaline combination
Mechanism of action
Indirectly and directly increases adrenergic tone and supports blood pressure; clinical effects of the marketed combination arise from cafedrine together with theodrenaline. A separate standalone mechanism or indication should not be inferred from the combination product.
Indications / reported uses
Component of the fixed cafedrine/theodrenaline combination used for treatment of acute hypotension, particularly during anaesthesia, in countries where the combination is authorised; not a standalone API indication
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cafedrine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cafedrine Permitted Daily Exposure (PDE) report (the Cafedrine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cafedrine Occupational Exposure Limit (OEL) report (the Cafedrine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.